Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex

被引:0
作者
Dhaenens, Britt A. E. [1 ,2 ]
van Dijk, Sarah A. [2 ,3 ]
Fertitta, Laura [4 ]
Taal, Walter [2 ,3 ]
Wolkenstein, Pierre [4 ]
Oostenbrink, Rianne [1 ,2 ,5 ]
机构
[1] Sophia Childrens Univ Hosp, Erasmus MC, Dept Gen Paediat, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands
[2] Erasmus MC, ENCORE Expertise Ctr Neurodev Disorders, Rotterdam, Netherlands
[3] Erasmus MC, Dept Neurol, Canc Inst, Dr Molewaterpl 40, NL-3000 CA Rotterdam, Netherlands
[4] Henri Mondor Univ Hosp, Assistance Publ Hop Paris, Natl Referral Ctr Neurofibromatosis, Dept Dermatol, Creteil, France
[5] European Reference Network Genet Tumour Risk Syndr, Nijmegen, Netherlands
关键词
Neurofibromatosis type 1; Cutaneous neurofibroma; Quality of life; QoL; Patient-reported outcome measure; cNF-Skindex; REPORTED OUTCOME MEASURES; CHILDREN; RESPONSIVENESS; INSTRUMENTS; PREVALENCE;
D O I
10.1186/s41687-024-00732-w
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Almost all patients with Neurofibromatosis type 1 (NF1) develop cutaneous neurofibroma (cNF), benign dermal tumours that have a large impact on the patient's Quality of Life (QoL). The French cNF-Skindex is the first questionnaire to specifically assess cNF-related QoL in patients with NF1. We aimed to adapt and validate a Dutch version of the cNF-Skindex.Methods The questionnaire was translated using forward and backwards translation, and subsequently administered to a sample of 59 patients on two separate occasions. Feasibility was evaluated by the presence of floor/ceiling effects. Reliability was assessed by evaluating internal consistency and test-retest reliability, by calculating Cronbach's alpha and Spearman's rank correlation coefficients. The EQ-5D-5L and SF-36 were used to evaluate convergent validity, using Spearman's rank correlation coefficients. An exploratory factor analysis was performed to study the data's internal structure. Multivariable linear regression was used to model the relationship between patient characteristics and the cNF-Skindex.Results The Dutch cNF-Skindex demonstrated excellent feasibility and reliability (Cronbach's alpha 0.96, test-retest correlation coefficient 0.88). Convergent validity was confirmed for the EQ-5D-5L and relevant SF-36 scales. All items and subdomains from the original questionnaire were confirmed following exploratory factor analysis. The patient characteristics included in the multivariable linear regression were not significantly associated with the cNF-Skindex score.Conclusions The Dutch cNF-Skindex displayed excellent psychometric properties, enabling use in the Netherlands.
引用
收藏
页数:8
相关论文
共 27 条
[1]   Neurofibromatosis type 1: New insights into neurocognitive issues [J].
Acosta, Maria T. ;
Gioia, Gerard A. ;
Silva, Alcino J. .
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2006, 6 (02) :136-143
[2]   Responsiveness of five condition-specific and generic outcome assessment instruments for chronic pain [J].
Angst, Felix ;
Verra, Martin L. ;
Lehmann, Susanne ;
Aeschlimann, Andre .
BMC MEDICAL RESEARCH METHODOLOGY, 2008, 8 (1)
[3]   VALIDATING THE SF-36 HEALTH SURVEY QUESTIONNAIRE - NEW OUTCOME MEASURE FOR PRIMARY CARE [J].
BRAZIER, JE ;
HARPER, R ;
JONES, NMB ;
OCATHAIN, A ;
THOMAS, KJ ;
USHERWOOD, T ;
WESTLAKE, L .
BMJ-BRITISH MEDICAL JOURNAL, 1992, 305 (6846) :160-164
[4]   Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases [J].
Chren, MM ;
Lasek, RJ ;
Sahay, AP ;
Sands, LP .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2001, 5 (02) :105-110
[5]   Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1 [J].
Ehara, Yuko ;
Yamamoto, Osamu ;
Kosaki, Kenjiro ;
Yoshida, Yuichi .
JOURNAL OF DERMATOLOGY, 2018, 45 (01) :53-57
[6]   Birth Incidence and Prevalence of Tumor-Prone Syndromes: Estimates From a UK Family Genetic Register Service [J].
Evans, D. G. ;
Howard, E. ;
Giblin, C. ;
Clancy, T. ;
Spencer, H. ;
Huson, S. M. ;
Lalloo, F. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2010, 152A (02) :327-332
[7]   Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults [J].
Fertitta, L. ;
Bergqvist, C. ;
Armand, M. L. ;
Moryousef, S. ;
Ferkal, S. ;
Jannic, A. ;
Ravaud, P. ;
Tran, V. T. ;
Ezzedine, K. ;
Wolkenstein, P. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (08) :1359-1366
[8]  
Fertitta L, 2023, J Invest Dermatol
[9]   Psychological Burden in Adult Neurofibromatosis Type 1 Patients: Impact of Disease Visibility on Body Image [J].
Granstroem, Sofia ;
Langenbruch, Anna ;
Augustin, Matthias ;
Mautner, Victor-Felix .
DERMATOLOGY, 2012, 224 (02) :160-167
[10]   Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey [J].
Guiraud, Marlene ;
Bouroubi, Athmane ;
Beauchamp, Roxane ;
Bocquet, Arnaud ;
Gregoire, Jean-Marc ;
Rauly-Lestienne, Isabelle ;
Blanco, Ignacio ;
Wolkenstein, Pierre ;
Schmitt, Anne-Marie .
ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (01)